The Human Biology Institute (HBI), the human health arm of Indian Immunology Limited, a subsidiary of the National Dairy Development Board (NDDB), celebrated its 25th anniversary on Saturday, marking a major milestone.
Established in 1998 to develop India’s first purified Vero cell rabies vaccine ‘Abhayrab’, HBI is committed to providing unparalleled quality and affordable vaccines to millions of people around the world. In 1999, the company entered the human vaccine market and established the Institute of Human Biology.
HBI’s belief in accessible life-saving biologics as a fundamental right has led to excellence in vaccine manufacturing through a commitment to innovation, relentless dedication and hard work. Today, it is the world’s largest manufacturer of anti-rabies vaccines and a major supplier of diphtheria-tetanus-pertussis-pertussis, hepatitis B and pentavalent vaccines for India’s universal immunization programme.
On the occasion of its 25th anniversary of the trust, HBI launched MebellaM – the measles-rubella (MR) vaccine and announced Havisure – India’s first indigenous hepatitis A vaccine, scheduled to be launched by March 2024.
K Anand Kumar, Managing Director, IIL said, “As outlined by the World Health Organization (WHO), the highly transmissible measles virus claims the lives of more than 100,000 children every year, while rubella causes birth defects and its global impact will follow us. The rollout of an affordable MR vaccine will significantly reduce this.”
“As a result of our tireless efforts, Mebella M is a live attenuated MR vaccine developed in exclusive collaboration with Polyvac Vietnam. Through extensive human clinical trials, Mebella M has been proven to be safe and effective in individuals aged 9 months to 49 years of age ‘s,” he added.
Discussing Hepatitis A, Priyabrata Pattnaik, Managing Director, IIL Dy said, “In India, the prevalence of Hepatitis A and its transmission through contaminated sources has slowly shifted from children to adolescents and adults. “This population is at risk of complications. increases, often requiring hospitalization. “
Patnaik highlighted the important role of vaccination for high-risk groups such as children, adolescents and food handlers, emphasizing its potential to prevent infections, complications and transmission.
With MebellaM and the upcoming Havisure® (hepatitis A vaccine), IndianImmunologicals Ltd (IL) reiterates its commitment to delivering innovative vaccines and addressing pressing healthcare challenges.
Indian Immunology Limited (IIL), a subsidiary of the National Dairy Development Board (NDDB), is the market leader in veterinary and human biologics in India. It produces more than 150 products. IIL is a major player in the Indian human vaccines market, focusing on pediatric and rabies vaccine segments. IIL is also a major supplier of pediatric vaccines to India’s large universal immunization programme.